key: cord-0829140-r7lbropw
authors: Turrini, M.; Gardellini, A.; Beretta, L.; Buzzi, L.; Ferrario, S.; Vasile, S.; Clerici, R.; Colzani, A.; Liparulo, L.; Scognamiglio, G.; Imperiali, G.; Corrado, G.; Strada, A.; Galletti, M.; Castiglione, N.; Zanon, C.
title: Clinical course and risk factors for in-hospital mortality of 205 patients with SARS-CoV-2 pneumonia in Como, Lombardy Region, Italy
date: 2021-03-05
journal: nan
DOI: 10.1101/2021.02.25.20134866
sha: 7793fa8379723c4dd48f16a1c2d4295e1b9b784c
doc_id: 829140
cord_uid: r7lbropw

Importance: With randomized clinical trials ongoing and vaccine still a long distance away, efforts to repurpose old medications used for other diseases provide hope for treatment of COVID-19. Objectives: To examine the risk factors for in-hospital mortality and describe the effectiveness of different treatment strategies in a real-life setting of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Design: Real-life single-center study during the Lombardy COVID-19 outbreak. Setting: Valduce Hospital in Como, Lombardy Region, Italy. Participants: 205 laboratory-confirmed patients presenting with SARS-Cov-2 pneumonia requiring hospitalization. Interventions: All patients received best supportive care and, based on their clinical needs and comorbidities, specific interventions that included the main drugs being tested for repurposing to treat COVID-19, such as hydroxychloroquine, anticoagulation, antiviral drugs, steroids or interleukin-6 pathway inhibitors. Main outcomes and measures: Clinical, laboratory and treatment characteristics were analyzed with univariate and multivariate logistic regression methods to explore their impact on in-hospital mortality and compared with current literature data. Results: Univariate analyses for clinical variables showed prognostic significance for age equal or greater than 70 years (estimated 28-days survival: 21.4 vs 67.4%; p<0.0001), presence of 2 or more relevant comorbidities (35.3 vs 61.8%; p=0.0008), ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F) less than 200 at presentation (21-days survival: 14.7 vs 52.4%;p<0.0001), high levels of lactate dehydrogenase (LDH) (26.4 vs 65.3%; p=0.0001), and elevated C-reactive protein (CRP) values (25.4 vs 74.9%; p=0.0001), while no statistical significance was found for all the other clinical variables tested. At univariate analysis for the different treatment scheduled, prognostic significance for survival was showed for intermediate or therapeutic-dose anticoagulation (estimated 28-days survival: 37.1 vs 23.4%; p=0.0001), hydroxychloroquine (35.7 vs 27.3%; p=0.0029), early antiviral therapy with lopinavir/ritonavir (60.1 vs 22.4%; p<0.0001), late short-course of steroids (47.9 vs 18.2%; p<0.0001) or tocilizumab therapy (69.4 vs 29.4%; p=0.0059). Multivariable regression confirmed increasing odds of in-hospital death associated with age older than 70 years (odds ratio 3.26, 95% CI 1.81 - 5.86; p<0.0001) and showed a reduction in mortality for patients treated with anticoagulant (-0.37, 0.49 - 0.95; p=0.0273), antiviral (-1.22, 0.16 - 0.54; p<0.0001), or steroids (-0.59, 0.35 - 0.87; p=0.0117) therapy.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID- 19) represents a viral disease infecting more than six million individuals all over the world and has emerged as one of the major public health emergencies of international concern. Therefore, on March 11th 2020 the World Health Organization (WHO) declared COVID-19 a pandemic disease because of widespread infectivity and high contagion rate. Full-genome sequencing indicated that COVID-19 is a betacoronavirus in the same subgenus as the severe acute respiratory syndrome (SARS) virus. The structure of the receptorbinding gene region is very similar to that of the SARS coronavirus, and the virus uses the same receptor, the angiotensin-converting enzyme 2 (ACE2), for cell entry [ 1 ] . Direct person-to-person transmission is the primary means of transmission of SARS-CoV-2, mainly through close-range contact via respiratory droplets or by transfer to mucous membranes after coming into contact with contaminated surfaces. The median incubation period for COVID-19 is between 2 and 12 days, with most cases occurring approximately four to five days after exposure [ 2 , 3 ] . Several studies describing the clinical features of COVID-19 have been performed in hospitalized populations [ 4, 5, 6 ]. The most common clinical characteristics at the onset of the disease were fever (even low-grade fever <38° C), cough, fatigue, and dyspnea with typical bilateral infiltrates on chest imaging. Other features, such as upper respiratory tract symptoms, myalgias, diarrhea, abdominal pain, anosmia and dysgeusia, may also be present [ 7 , 8 , 9 , 10 ]. The spectrum of symptomatic infection ranges from mild to critical, with a proportion of severe or critical disease reported in approximately 20% of cases [ 5, 11, 12 ]. Acute respiratory distress syndrome (ARDS) is the major complication in patients with severe disease and can manifest shortly after the onset of dyspnea [ 4, 21 ] . Other common complications include thromboembolic disorders, cardiovascular disease (eg, arrhythmias, acute cardiac injury, and shock), exuberant inflammatory response similar to cytokine release syndrome, and secondary infections [ 4, 13 , 14 , 15 , 16 , 17 , 18 ]. Severe illness can occur in otherwise healthy individuals of any age, but the highest proportion of severe cases occurs in adults older than 60 years of age or presenting underlying medical comorbidities. Potential risk factors for severe illness include cardiovascular and cerebrovascular diseases, diabetes mellitus, chronic lung disease, malignancies, and obesity [ 19, 20, 21, 22 ]. The most common laboratory abnormalities among hospitalized patients with COVID-19 include lymphopenia, elevated aminotransaminase, lactate dehydrogenase (LDH), and inflammatory markers such as C-reactive protein (CRP), ferritin, and erythrocyte sedimentation rate (ESR) [ 3, 4, 6, 23, 24, 25 ]. Common abnormal chest radiograph findings were consolidation and ground glass opacities, with bilateral, peripheral, and lower lung zone distributions [ 26 ] . Chest computed tomography (CT) studies confirm the presence of bilateral peripheral All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ground-glass opacification with or without consolidative abnormalities, while less common findings include pleural thickening, pleural effusion, and lymphadenopathy [ 27, 28, 29 ].

A number of approaches to COVID-19 therapy have been investigated, including chloroquine, antiviral drugs, interleukin-6 pathway inhibitors and other immunomodulators. In vitro studies have shown that hydroxychloroquine and chloroquine can bind cell surface sialic acid and gangliosides with high affinity, thereby impairing SARS-CoV-2 binding to host cell angiotensin converting enzyme (ACE)-2 receptors [ 30, 31 ].

On the basis of their potential antiviral activity in vitro, several randomized trials have been conducted to evaluate their clinical use, but none have suggested a clear efficacy [ 32, 33, 34 ]. Most observational studies have also not suggested a benefit with chloroquine or hydroxychloroquine treatment [ 35, 36 ], and highlighted the potential risk for toxicity of those drugs. Arrhythmias and QTc prolongation emerged as the most relevant adverse events, particularly when these agents are administered in patients with comorbidities or in combination with other medicines known to prolong the QT interval, including azithromycin. Antiviral agent lopinavir/ritonavir has been considered as a promising treatment option for COVID-19 infections, based on its proven in vitro efficacy against other novel coronaviruses SARS-COV via inhibition of 3-chymotrypsin-like protease [ 37, 38 ]. However, results from a randomized trial do not demonstrate a clear benefit of lopinavirritonavir compared with standard care alone, at the cost of increased toxicity [ 39 ] . Due to the observation that some patients have a marked elevation in pro-inflammatory markers with a clinical presentation that resembles cytokine release syndrome, interrupting the inflammatory cascade has been proposed as a potential therapeutic target for COVID-19 to prevent disease progression. Tocilizumab, an interleukin(IL)-6 receptor inhibitor, is being evaluated in randomized trials for treatment of COVID-19. Similarly, glucocorticoids have been used in patients with moderate to severe ARDS.

Here, we report the epidemiological, clinical, and laboratory characteristics, treatment and clinical outcomes of 205 laboratory-confirmed cases infected with SARS-CoV-2 admitted to Valduce Hospital in Como, Italy.

The aim of this study is to explore risk factors for in-hospital mortality and describe the effectiveness of different treatment strategies in a real-life single-center cohort.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Two hundred and five patients aged between 17 and 100 years (male/female: 113/92) were admitted to Valduce hospital because of SARS-Cov-2 pneumonia requiring hospitalization and were included in this analysis. One hundred and sixty-eight patients came to direct observation in the emergency room, while 37 patients were sent to the hospital from a nursing home for the elderly. All patients had a laboratory-confirmed SARS-CoV-2 infection through RT-PCR on nasopharyngeal swab specimen. For each patient, data regarding history, vital signs, ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F), need for oxygen therapy, blood chemistry parameters, treatment schedule and outcome were recorded. Blood chemistry variables were recorded both as value at presentation and as maximum value achieved during hospitalization, while interleukin 6 (IL6) values were recorded only in 29 patients candidate for tocilizumab therapy. Patients' characteristics at presentation are shown in Table 1 . Overall, hydroxychloroquine (HCQ) was administered to 160 patients (78%) with a loading dose of 400 mg bid followed by maintenance with 200 mg die for 7-14 days. Antiviral therapy was administered to 52 patients (25.3%) and consisted in lopinavir/ritonavir 400/100 mg bid for 5-7 days. Since only 2 patients were treated with remdesivir on a compassionate-use basis, this treatment was not included in the statistical analysis. Almost all patients (95.6%) were treated with a concomitant short course of antibiotic therapy, usually including azithromycin 500 mg die for 3 to 6 days. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The need for oxygen therapy was distinguished based on the amount of oxygen delivered to maintain an adequate P/F ratio. Oxygen delivery systems were classified as low-flow or variable-performance devices and high-flow or fixed-performance devices. Low-flow systems provide oxygen at flow rates that are lower than patients' inspiratory demands, where high-flow systems provide a constant FiO 2 by delivering the gas at flow rates that exceed the patient's peak inspiratory flow. Oxygen was delivered using nasal cannulas (n 32), bag-valve masks (n 36), Venturi mask (n 41) or continuous positive airway pressure (CPAP, n 64). Sixteen patients (7.8%) did not need for oxygen therapy, while 16 patients (7.8%) were transferred to the Intensive Care Unit for orotracheal intubation (IOT).

All collected variables were submitted to descriptive methods. For continuous variables the distribution was firstly evaluated by the Shapiro-Wilk test, so that normally distributed variables were summarized with mean and standard deviation, while non-normal variables were summarized as median, range and interquartile range. Pearson's chi-square test with Yates' correction for continuity and Fisher's exact test (if applicable) were used to check the association between categorical data, after cross-tabulation. Comparisons of normally distributed continuous variables were carried out by Student's t-test or by Welch's test (in the case of non-homogeneous variances between groups, previously verified by Levene's test). The Mann-Whitney U test was used for comparison of continuous non-normally distributed variables. The survival analysis was carried out using the Kaplan-Meier product limit method, followed by the logrank test, to evaluate the possible differences in survival between groups. Cox univariate and multivariate regression models were also used to analyse the effects of continuous variables on survivorship. The optimal multivariate model was chosen using a backward stepwise elimination after inserting all variables showing p < 0.05 at univariate analysis. The receiver operating characteristics curve (ROC) was traced to analyse the role of continuous variables on survivorship and to search for an optimal cut-off value for variables themself. For all possible cut-off points, the total accuracy was considered together with sensitivity, specificity, positive predictive value and negative predictive value; however, the choice was made according to Youden. Statistical significance was assumed for all tests with p <.05. Statistical analysis was done using MedCal 9.3.7.0.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Two hundred and five patients were included in the analysis. The median follow-up time was 16 days based on the reverse Kaplan-Meier method. The median hospitalization time was 7 days (range: 1-27) and 12 days (range: 1-43) in deceased and surviving patients, respectively. Among the 107 surviving patients (52.2%), 58

were discharged from the hospital and 49 were transferred to rehabilitation facilities. The estimated 7-days and 28-days survival resulted 69.4% and 34.1%, respectively ( Figure 1 ). Statistical analysis showed no significant difference in term of clinical variables between male and female patients.

Cox univariate and multivariate regression models were performed for all patients to evaluate the role of different clinical variables as predictors for in-hospital mortality. The following potential prognostic parameters were evaluated: age, sex, comorbidities, P/F ratio, oxygen therapy, white blood cell count (WBC), All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Finally, univariate analysis was tested for survival for the different treatment scheduled (Figure 4A-F Table 2 ).

Based on ROC curve analysis, inflammation markers CRP and LDH were incorporated into a prognostic score system, attributing 1 point for each value above the identified cut-off (nominally, 124 mg/L for CRP and 395 U/L for LDH). Having none, one or both of the positive markers determined a reduction in estimated 28days survival from 94.0% to 51.3% and 21.0%, respectively (logrank test: p < 0.0001)( Figure 5 ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ]. In a modeling study based on Chinese data, the hospitalization rate for COVID-19 increased with age, with a 11.8% rate for those 60 to 69 years old, 16.6% rate for those 70 to 79 years old, and 18% for those older than 80 years [ 40 ] . Older age has also been associated with more severe disease and increased fatality rate, though there is no clear age cut-off [ 11, 22, 41 ]. In a report from the Chinese Center for Disease Control and Prevention, mortality rates were 8 and 15% among those aged 70 to 79 years and 80 years or older, respectively, in contrast to the 2.3% case fatality rate among the entire cohort . In accordance with these data, in our study 57.6% of patients had two or more preexisting comorbidities among those considered potential risk factors for severe COIVD-19 disease. Survival analysis showed prognostic significance for comorbidities, but the significance was not retained when tested against other clinical and therapeutic variables in multivariate analysis.

Several laboratory features may be altered among hospitalized patients with COVID-19. High D-dimer levels and severe lymphopenia have been associated with critical illness, while procalcitonin levels on admission are more likely to be elevated in patients requiring ICU care [ 4, 5, 7 ]. Elevated lactate dehydrogenase, C-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ]. However, none of these characteristics have clearly demonstrated to have a strong prognostic value. In our patient population LDH, CRP and IL-6 showed an optimal cut-point for survival on ROC curve analysis, while we found no significance for the other laboratory test WBC, PCT, ferritin, and Ddimer. Based on these data, inflammation markers CRP and LDH have been incorporated into a prognostic score system, which has been shown to recognize 3 distinct groups of patients characterized by different disease severity and clinical outcome. Validation of this potential easy-to-apply clinical score is required on a larger prospective patient population. In accordance with these literature data, in our patient cohort HCQ was safely administered to 160 patients and no treatment-related adverse events were recorded. Although HCQ treatment showed prognostic significance for survival at univariate analysis, significance was not confirmed in the multivariate analysis (p 0.146). Finally, several Drug Agencies from different countries now recommend not to use hydroxychloroquine or chloroquine outside the setting of a clinical trial, given the lack of clear benefit from limited data and potential for toxicity. A multi-centre, adaptive, randomized, open clinical trial of the safety and efficacy of treatments for COVID-19, including HCQ, in hospitalized adults is now ongoing (NCT04315948). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The combined protease inhibitor lopinavir/ritonavir, primarily used for HIV infection, has demonstrated an in vitro activity against the SARS-CoV via inhibition of 3-chymotrypsin-like protease [ 37, 38 ]. In a multicentric retrospective matched cohort study conducted during the SARS outbreak the addition of lopinavir/ritonavir as initial treatment was associated with a statistically significant reduction in the overall death rate and intubation rate compared with matched controls [ 43 ] . In addition, a significant reduction in adverse events such as severe respiratory deterioration and lower nosocomial infections were also noted in patients treated with lopinavir/ritonavir, and significance was confirmed at multivariate analysis [ . Though there was a trend towards decreased mortality (particularly when administered within 12 days of symptom onset) and a reduction in serious adverse events, treatment with lopinavir/ritonavir was not associated with a difference in the time to clinical improvement nor in mortality at 28 days. Furthermore, the timing of lopinavir/ritonavir administration during the early peak of viral replication phase (initial 7-10 days) appears to be crucial, since delayed therapy initiation showed no effect on clinical outcomes [ 43, 44 ].

In our study, short-term antiviral therapy was administered to 52 patients early on admission and within 7 days of symptom onset. Furthermore, particular attention had been paid to possible drug-drug interactions, with only a few low-grade transient gastrointestinal events and no serious treatment-related adverse. At univariate analysis, antiviral therapy showed prognostic significance for survival, with a clear benefit in term of 28-days survival. When combined in the multivariate analysis, antiviral therapy proved to be an independent risk factors for survival. The WHO has recently launched the multinational SOLIDARITY trial to further evaluate the activity of those anti-viral treatment in COVID-19 disease.

Markedly elevated inflammatory markers (eg, D-dimer, ferritin) and elevated pro-inflammatory cytokines as interleukin (IL)-6 are associated with severe COVID-19 disease, and blocking the inflammatory pathway has been hypothesized to prevent disease progression [ 15 ] . Glucocorticoids were the first drugs introduced with this aim [ 5, 7 ]. Based on data reporting potential benefit of glucocorticoids in patients with moderate to severe ARDS, a weak recommendation in favor of such therapy has been provided in this population. However, glucocorticoids administration in critically ill patients with COVID-19-related ARDS is not suggest routinely, since data are limited to a single retrospective Chinese cohort [ 12 ] and there is concerning about a delayed viral clearance in patients with ARDS due to viral pneumonia. In our cohort, glucocorticoids were administered in patients still needing oxygen therapy at the end of the viral replication phase (ie, after more than 7 days from the onset of symptoms), and consisted in a short course of methylprednisolone up to 1 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ]. In a retrospective series of more than 2500 hospitalized patients with COVID-19, anticoagulation was associated with improved in-hospital All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ] . In a retrospective study of individuals with severe COVID-19, LMWH appeared to be associated with improved survival when compared with no pharmacologic prophylaxis, especially in patients with high D-dimer levels [ 56 ] . Reports from ICU patients with severe COVID-19 suggest a higher incidence of venous thrombosis embolism, even using standard prophylaxis [ 57, 58 ]. The question of adequate anticoagulation dose for thromboprophylaxis has also been raised in COVID-19 patients. There are no actual data comparing prospectively the different levels of Interestingly, we found no difference in term of 28-days survival between patients treated with intermediatedose or therapeutic-dose anticoagulation for previous medical issues. In contrast, thromboprophylaxis at any dose appears to be associated with improved survival when compared with no pharmacologic prophylaxis, and significance is maintained even when combined in multivariate analysis.

Our study has several limitations due to the retrospective nature of the study. Overall, we found that age at the onset of SARS-CoV-2 disease is a powerful predictor of in-hospital mortality. In addition, intermediate or therapeutic-dose anticoagulation, early short-term antiviral therapy and short course of corticosteroids at the end of the viral replication phase proved to be effective treatments in COVID-19 disease. Interestingly, hydroxychloroquine therapy has not been confirmed as significant in the treatment of SARS-CoV-2 infection, in accordance with latest literature data. Finally, impairment in inflammation markers can find application as predictors of poor outcomes for hospitalized patients when incorporated into an easy-to-use prognostic score, helping clinicians to identify patients with poor prognosis at an early stage. Confirmation from a validation cohort is expected. Results from this real-life single-center experience are in agreement and confirm actual literature data on SARS-CoV-2 pneumonia, both in terms of risk factors for in-hospital mortality and as regards the effectiveness of the different therapies proposed for the management of COVID-19 disease.

Results from randomized clinical trials are expected.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application

Clinical Characteristics of Coronavirus Disease 2019 in China. China Medical Treatment Expert Group for Covid-19

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Covid-19 in New York City

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis

Epub ahead of print

Loss of Smell and Taste in

European Patients With Mild to Moderate COVID-19

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Prevalence and impact of cariovascular metabolic disease on COVID-19 in China

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Molecular and serological investigation of 109-nCoV infected patients: implicationof multiple shedding routes

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in singapore

Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic

Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of cornavirus disease (COVID-19) during early outbreak period: a scoping review

Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Association of Treatment With Hydroxychloroquine or

Azithromycin With In-Hospital Mortality in Patients With COVID-19 in

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

A systematic review of lopinavir therapy fo SARS coronavirus and MERS coronavirus. A possible reference for coronavirus disease-19 treatment option

Tocilizumab treatment in COVID-19: A single center experience

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Why tocilizumab could be an effective treatment for severe COVID-19?

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

Tocilizumab for treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia

Increased sFLT1/PlGF ratio in COVID-19: a novel link to Angiotensin II-mediated endothelial dysfunction

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Hypothesis for pothential pathogenesis of SARS-CoV-2 infection: a review of immune changes in patients with viral pneumonia

COVID-19 and its implications for thrombosis and coagulation

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Incidence of venous thromboembolism in hospitalized patients with COVID-19

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

ZC conceived the study and is responsible for the overall content as guarantor. BL and BL collected the data and provided operational support. TM validated data collection, performed the literature search, conducted the statistical analyses, and drafted the manuscript. GA performed the literature search, contributed in drafting the manuscript and to critical revision of the report. All authors were involved in the clinical management of patients, discussed the results and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria.All authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.We acknowledge the Valduce Hospital COVID-19 task force and all clinicians, nurses and health-care workers involved in the diagnosis and treatment of patients in Como, Italy.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.02.25.20134866 doi: medRxiv preprint